## KKR: KKR & Co. Inc. - XLF: Financial Services

### Executive Summary

VALUE thesis: PEG 0.53 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (52% of avg), momentum weakening (-2.2% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($122.38)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. KKR gets first negotiation rights to take Yomeishu private**
- Source: The Japan Times | 20251230T060805 | Bullish | Relevance: 100%
- U.S. investment firm KKR has secured first negotiation rights to acquire Yomeishu Seizo, a Japanese herbal health tonic manufacturer, marking a significant step in Japan's brisk corporate deal-making year. KKR intends to finalize terms, including the purchase price, and initiate a tender offer for Yomeishu in January. Yomeishu's shares surged by 14% following the news, increasing its market value by approximately ¥11.3 billion.

**2. KKR Acquires Cheongna Logistics Center**
- Source: FinancialContent | 20251229T210900 | Bullish | Relevance: 100%
- KKR and its Korean affiliate, Kreate Asset Management, have completed the acquisition of Cheongna Logistics Center in Incheon, making it the largest single asset logistics transaction in South Korea to date. The 4.6-million square feet facility, completed in 2022, is fully occupied and strategically located to support Korea's e-commerce-driven economy. Kreate will manage the center, with KKR supporting value creation strategies and maintaining asset quality.

**3. KKR Secures Exclusive Talks to Take Yomeishu Private**
- Source: TradingView — Track All Markets | 20251229T120817 | Bullish | Relevance: 100%
- KKR has secured exclusive negotiation rights to potentially take Japanese herbal health tonic maker Yomeishu Seizo private. The private equity firm aims to finalize terms, including a purchase price, for a tender offer possibly in January 2026. The deal, valued around 79 billion yen, requires agreement with Yomeishu's largest shareholder, Yuzawa KK, and aligns with Japan's corporate governance reforms.

**4. KKR Completes Acquisition of Major Logistics Facility in Korea**
- Source: GuruFocus | 20251230T130530 | Neutral | Relevance: 100%
- KKR, in collaboration with Kreate Asset Management, has completed the acquisition of the Cheongna Logistics Center in Incheon, making it the largest logistics transaction in Korea. While this expands KKR's investment in Korean logistics, the company faces financial challenges, including declining revenue and profitability, and shows potential financial instability according to its Altman Z-Score. Investors are advised to consider the high valuation and warning signs despite the strategic acquisition.

**5. KKR, Kreate acquire South Korea's Cheongna Logistics Center**
- Source: Reuters | 20251230T100830 | Bullish | Relevance: 100%
- Global investment firm KKR and its affiliated Korean asset manager, Kreate Asset Management, have acquired the Cheongna Logistics Center in South Korea. This deal, valued at over 1 trillion won ($696 million) including debt, is considered South Korea's largest single-asset logistics transaction. The 4.6-million-square-foot facility is fully leased and strategically located within the Greater Seoul metropolitan area, highlighting the growing demand for large, high-specification warehouses due to the e-commerce boom.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Barclays | $169 | $154 | +10% |
| 2025-12-11 | UBS | $176 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Barclays | main | Overweight |
| 2025-12-11 | UBS | init | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 14 ($2.87M) |
| Sells | 2 ($424.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 6.7% (+1.0%)
- Blackrock Inc.: 5.4% (-1.1%)
- Capital Internationa: 3.5% (-1.4%)
- State Street Corpora: 3.1% (+1.6%)
- Wellington Managemen: 2.7% (+1.3%)

### Key Risks

1. High beta (2.00) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_20 falling (-2.2% 5d) with bearish MACD, trend may be turning.
3. Heavy insider selling: $424M sold (2 transactions in 90 days).

### Catalysts

- M&A activity or partnership announcements may unlock value.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.53 indicates undervaluation relative to growth. Forward P/E 18.9x attractive for 32% earnings growth. Balance sheet: strong liquidity (4.2x), $2.4B free cash flow. Revenue growth strong at 29% YoY. Analyst sentiment positive (1 raises, avg +10%). Insider selling cluster ($424.4M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $119.1B |
| Beta | 2.00 |
| 52W Range | $86.15 - $170.40 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.53 |
| Forward P/E | 18.9 |
| Current P/E | 25.0 |
| YoY Growth | 32.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.4% to -2.6% (-2.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.6pp (needs >4.0% for momentum thesis). Underperforming sector by 3.9pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.01x) but short-term weakness (below SMA20). MACD histogram bearish (-0.90), momentum weakening. RSI neutral at 49. Volume at 52% of 20MA suggests lack of conviction. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.60% (CS: 16) | Weak |
| RSI_14 | 48.7 | Neutral |
| MACD Histogram | -0.90 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 1.033x | Above |
| vs SMA200 | 1.011x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $128.68
- **Stop Loss:** $122.38 (4.9% risk)
- **Target:** $141.28 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 130
- **Position Value:** $16,728.40
- **Portfolio %:** 16.73%
- **Risk Dollars:** $825.00
- **Risk Per Trade:** 0.83%
- **Modifiers:** L1 110% | L2 75% | Combined 0.83x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-06 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.41 | +8.6% |
| 2025Q2 | $1.14 | $1.18 | +3.6% |
| 2025Q1 | $1.13 | $1.15 | +1.7% |
| 2024Q4 | $1.28 | $1.32 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*